Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Harrison

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Journal of Substance Use and Addiction Treatment|August 31, 2023
The mobilization of nurse-client therapeutic relationships in injectable opioid agonist treatment: Autonomy, advocacy and actionSarin Blawatt, Scott Harrison, David Byres, et al.
BMC Genetics|June 7, 2011
Interpopulation hybridization results in widespread viability selection across the genome in Tigriopus californicusVictoria L Pritchard, Leilani Dimond, J Scott Harrison, et al.
Drug and Alcohol Dependence|September 5, 2022
Harm reduction in the hospital: An overdose prevention site (OPS) at a Canadian hospitalSeonaid Nolan, Salpy Kelian, Thomas Kerr, et al.
Harm Reduction Journal|February 5, 2022
Implementation of a nurse-led overdose prevention site in a hospital setting: lessons learned from St. Paul's Hospital, Vancouver, CanadaElizabeth Dogherty, Carlin Patterson, Marilou Gagnon, et al.
Substance Abuse Treatment, Prevention, and Policy|September 30, 2023
The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic reviewAlison Adams, Sarin Blawatt, Tianna Magel, et al.
The International Journal on Drug Policy|May 14, 2023
Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic reviewAlison Adams, Sarin Blawatt, Scott MacDonald, et al.
Journal of Addiction Medicine|February 13, 2019
Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use DisorderEugenia Oviedo-Joekes, Heather Palis, Daphne Guh, et al.
The International Journal on Drug Policy|December 31, 2022
Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling)Sophia Dobischok, Rebecca Metcalfe, Elizabeth Matzinger, et al.
Journal of Substance Abuse Treatment|June 7, 2021
A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use researchKirsten Marchand, Heather Palis, Daphne Guh, et al.
Journal of Addiction Medicine|February 8, 2020
Physician Communication in Injectable Opioid Agonist Treatment: Collecting Patient Ratings With the Communication Assessment ToolHeather Palis, Kirsten Marchand, Scott Beaumont, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Journal of Substance Use and Addiction Treatment|August 31, 2023
The mobilization of nurse-client therapeutic relationships in injectable opioid agonist treatment: Autonomy, advocacy and actionSarin Blawatt, Scott Harrison, David Byres, et al.
BMC Genetics|June 7, 2011
Interpopulation hybridization results in widespread viability selection across the genome in Tigriopus californicusVictoria L Pritchard, Leilani Dimond, J Scott Harrison, et al.
Drug and Alcohol Dependence|September 5, 2022
Harm reduction in the hospital: An overdose prevention site (OPS) at a Canadian hospitalSeonaid Nolan, Salpy Kelian, Thomas Kerr, et al.
Harm Reduction Journal|February 5, 2022
Implementation of a nurse-led overdose prevention site in a hospital setting: lessons learned from St. Paul's Hospital, Vancouver, CanadaElizabeth Dogherty, Carlin Patterson, Marilou Gagnon, et al.
Substance Abuse Treatment, Prevention, and Policy|September 30, 2023
The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic reviewAlison Adams, Sarin Blawatt, Tianna Magel, et al.
The International Journal on Drug Policy|May 14, 2023
Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic reviewAlison Adams, Sarin Blawatt, Scott MacDonald, et al.
Journal of Addiction Medicine|February 13, 2019
Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use DisorderEugenia Oviedo-Joekes, Heather Palis, Daphne Guh, et al.
The International Journal on Drug Policy|December 31, 2022
Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling)Sophia Dobischok, Rebecca Metcalfe, Elizabeth Matzinger, et al.
Journal of Substance Abuse Treatment|June 7, 2021
A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use researchKirsten Marchand, Heather Palis, Daphne Guh, et al.
Journal of Addiction Medicine|February 8, 2020
Physician Communication in Injectable Opioid Agonist Treatment: Collecting Patient Ratings With the Communication Assessment ToolHeather Palis, Kirsten Marchand, Scott Beaumont, et al.
Pageof 7